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Abstract
Bone is the most common site of metastasis for breast cancer, however the reasons for this remain unclear. We hypothesise
that under certain conditions mammary cells possess osteomimetic capabilities that may allow them to adapt to, and
flourish within, the bone microenvironment. Mammary cells are known to calcify within breast tissue and we have recently
reported a novel in vitro model of mammary mineralization using murine mammary adenocarcinoma 4T1 cells. In this study,
the osteomimetic properties of the mammary adenocarcinoma cell line and the conditions required to induce
mineralization were characterized extensively. It was found that exogenous organic phosphate and inorganic phosphate
induce mineralization in a dose dependent manner in 4T1 cells. Ascorbic acid and dexamethasone alone have no effect. 4T1
cells also show enhanced mineralization in response to bone morphogenetic protein 2 in the presence of phosphate
supplemented media. The expression of several bone matrix proteins were monitored throughout the process of
mineralization and increased expression of collagen type 1 and bone sialoprotein were detected, as determined by real-time
RT-PCR. In addition, we have shown for the first time that 3D collagen glycosaminoglycan scaffolds, bioengineered to
represent the bone microenvironment, are capable of supporting the growth and mineralization of 4T1 adenocarcinoma
cells. These 3D scaffolds represent a novel model system for the study of mammary mineralization and bone metastasis. This
work demonstrates that mammary cells are capable of osteomimicry, which may ultimately contribute to their ability to
preferentially metastasize to, survive within and colonize the bone microenvironment.
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Introduction
Bone is one of the most preferential metastatic target sites for
breast cancers [1], although the precise molecular mechanisms
underlying this preference have yet to be elucidated. Mammary
cells are known to mineralize, giving rise to mammographic
microcalcifications, which are routinely used for the early de-
tection of breast cancer. Up to 50% of all nonpalpable breast
cancers and up to 90% of ductal carcinoma in situ (DCIS) are
detected through mammographic microcalcifications [2,3]. On
a molecular level, there are two distinct forms of mammary
microcalcifications; calcium oxalate and hydroxyapatite [4].
Calcium oxalate is mostly associated with benign breast lesions,
whereas hydroxyapatite is associated with both benign and
malignant breast tumors [5,6,7]. Hydroxyapatite is also a well
documented component of bone, the deposition of which in bone
tissue requires the coordinated expression of several bone matrix
proteins, synthesized by cells of the osteoblastic lineage [8].
The functional role of hydroxyapatite deposition within the
breast tumor microenvironment has been largely overlooked in the
literature. However, we have previously shown that exogenous
hydroxyapatite enhances the mitogenesis of mammary cell lines in
vitro [9], suggesting that the presence of hydroxyapatite calcifica-
tions could potentially aggravate tumor growth. We have also
demonstrated that hydroxyapatite upregulates the production of
matrix metalloproteinases (MMPs) in mammary cell lines [9].
MMPs are well known to be involved in the degradation of the
basement membrane, facilitating cancer cells metastasizing to
surrounding tissues [10]. More recently, we have shown that
hydroxyapatite enhances migration of a metastatic mammary cell
line, whereas calcium oxalate has no effect [11], again suggesting
that hydroxyapatite deposition may contribute to the metastatic
process. We have also recently demonstrated that invasive
mammary cell lines are capable of producing hydroxyapatite in
vitro when exposed to an osteogenic cocktail [11]. A mechanism for
mammary cell mineralization was proposed which centered on an
imbalance between the enhancers and inhibitors of physiological
mineralization [11]. Other studies have reported an overexpres-
sion of several bone matrix proteins, including bone sialoprotein,
osteopontin and osteonectin, in breast cancer biopsies containing
microcalcifications [12,13].
We hypothesise that osteomimicry may represent an overlooked
property of breast cancer cells that could contribute to the
metastatic process by ensuring the cancer cells are primed to
survive within the bone microenvironment. In this study we
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identify the components within the osteogenic cocktail essential for
mineralization and we investigate whether mammary cells, which
are capable of depositing hydroxyapatite, do so in a manner
similar to osteoblasts. In addition, we examine the potential of 3D
collagen scaffolds, engineered to represent the bone microenvi-
ronment, as a model for bone metastasis.
Results
b-glycerophosphate Alone is Sufficient to Induce
Mineralization of 4T1 Cells
We have previously established that the metastatic mouse
mammary 4T1 cell line is capable of mineralizing in the presence
of an osteogenic cocktail, which consists of ascorbic acid and b-
glycerophosphate with or without dexamethasone. A typical
mineralizing nodule is shown in Figure S1 (Figure S1) in the
supporting information. In this study the contribution of the
individual components of the osteogenic cocktail used to induce
mineralization was investigated. Positive staining for calcium (red)
and calcium phosphate (black/brown) was observed with alizarin
red S and von Kossa staining respectively after 14 days of
treatment in the presence of 10 mM b-glycerophosphate alone,
which was comparable to the staining observed in the osteogenic
cocktail group (50 mg/ml ascorbic acid, 10 mM b-glyceropho-
sphate ) at this time point (Figure 1). Positive staining was also
detected in the osteogenic cocktail with dexamethasone group
(50 mg/ml ascorbic acid, 10 mM b-glycerophosphate with
100 nM dexamethasone), but to a lesser extent than OC without
dexamethasone. No positive staining was detected in response to
treatment with ascorbic acid alone or dexamethasone alone, which
was comparable to the control group grown in regular growth
media.
4T1 Cells Mineralize in Response to b-glycerophosphate
in a Dose Dependent Manner
4T1 cells were grown in culture plates for 28 days in the
presence of regular growth media (control), the osteogenic cocktail
(OC; 10 mM b-glycerophosphate and 50 mg/ml ascorbic acid),
and increasing concentrations of b-glycerophosphate (bG; 2 mM,
5 mM and 10 mM). Positive staining for calcium was detected in
the 10 mM bG group beginning on day 14 using alizarin red S
(Figure 2A), with the intensity of the stain increasing over time up
to day 28. Faint positive staining was detected in the 5 mM and
2 mM bG groups by day 28. These results were also confirmed
using von Kossa staining, as shown by the day 28 representative
images (Figure 2B). Positive staining for calcium phosphate (black/
brown) was observed in the 5 mM and 10 mM bG group by this
time point. A calcium assay was also used to quantify the results
(Figure 2C). The greatest increase in calcium levels over time was
observed in the OC group (P,0.001 vs. control on days 14, 21
and 28). In addition, by day 28 an 80-fold increase in calcium
levels was detected in the 10 mM bG group, a 14-fold was
observed in the 5 mM bG group and a 3.5-fold increase was
detected in the 2 mM bG group, indicating a dose response. No
changes in calcium normalized to protein were detected in the
control group over time.
4T1 Cells Mineralize in Response to Inorganic Phosphate
in a Dose Dependent Manner
Having established that the 4T1 cells are capable of mineral-
izing in the presence of organic phosphate, the effect of inorganic
phosphate was also investigated. The 4T1 cells were grown in
culture plates for 28 days in the presence of regular growth media
(control), the osteogenic cocktail (OC; 10 mM b-glycerophosphate
and 50 mg/ml ascorbic acid), AA&10 mM Pi (10 mM inorganic
phosphate and 50 mg/ml ascorbic acid) and increasing concentra-
tions of inorganic phosphate alone (Pi; 2 mM, 5 mM and 10 mM).
The 4T1 cells began to stain positive for calcium (red; alizarin red
S staining) on day 7 when treated with AA&10 mM Pi, 5 mM Pi
alone or 10 mM Pi alone (Figure 3A). This staining increased in
intensity over time, with the strongest staining in the 10 mM Pi
group. Faint positive staining was observed in the 2 mM Pi group
by day 28. A similar delayed pattern of staining for calcium
phosphate (black/brown) was also observed as shown by
representative day 28 von Kossa images (Figure 3B). Positive
staining was observed in the OC, AA&10 mM Pi, 5 mM Pi and
10 mM Pi, with the strongest staining again in the 10 mM Pi
group. A calcium assay was used to quantify the increase in
cellular calcium (Figure 3C). Increases in calcium were detected
for the OC group over time (P,0.05 day 28 vs. control group).
However, the calcium levels for the AA&10 mM Pi, 5 mM Pi and
10 mM Pi groups were all consistently higher than the OC group
at each time point and were elevated from day 7 onwards. The
largest increase in calcium levels were detected in the 10 mM Pi
group on day 28 (P,0.001 vs. control group).
Figure 1. Investigating the effect of the individual components of the osteogenic cocktail on 4T1 cell mineralization. Alizarin red S
and von Kossa staining are positive for calcium (red) and calcium phosphate (black/brown) respectively in the OC, OC&dex and bG groups on day 14.
No positive staining was observed in the control, AA or dex groups. Representative images were taken at 1006magnification (n = 3) and the scale bar
represents 500 mm. Control = regular growth media. AA= 50 mg/ml ascorbic acid. bG=10 mM b-glycerophosphate. OC (osteogenic cocktail) = 50 mg/
ml AA and 10 mM bG. Dex = 100 nM dexamethasone.
doi:10.1371/journal.pone.0041679.g001
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Figure 2. Investigating the effect of increasing concentrations of b-glycerophosphate on 4T1 cell mineralization. Representative
images were captured at 1006magnification and the scale bars represent 500 mm. (A) Positive alizarin red S staining for calcium (red) was observed
in the OC, 5 mM bG and 10 mM bG treated groups, beginning on days 14, 28 and 14 respectively. (B) Positive von Kossa staining for calcium
phosphate (black/brown) was observed in the OC, 5 mM bG and 10 mM bG treated groups on day 28. (C) The calcium content of 4T1 cells as
determined by the o-cresolphthalein calcium assay and normalized to protein. Increases in calcium were observed in the OC and 10 mM bG treated
groups over time. Each point represents the mean amount of calcium measured in ppm normalized to protein measured in mg, +/2 SEM, n= 3, two-
way ANOVA. *P,0.05, ***P,0.001 vs. control at each time point. OC (osteogenic cocktail) = 50 mg/ml ascorbic acid and 10 mM b-glycerophosphate.
bG=b-glycerophosphate.
doi:10.1371/journal.pone.0041679.g002
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BMP2 Enhances Mineralization of 4T1 Cells in the
Presence of the Osteogenic Cocktail
4T1 cells were seeded into culture plates and grown for up to 14
days in the presence of regular growth media (control), the
osteogenic cocktail (OC; 50 mg/ml ascorbic acid and 10 mM b-
glycerophosphate in regular growth media), human recombinant
bone morphogenetic protein 2 (BMP2: 100 ng/ml BMP2 in
regular growth media) or BMP2 in combination with the
osteogenic cocktail (OC&BMP2). No positive staining for calcium
(red) or calcium phosphate (black/brown) was detected using
alizarin red S and von Kossa staining respectively, in the control
group or the BMP2 alone group for up to 14 days (Figures 4A and
4B). Positive alizarin red S and von Kossa staining was observed in
the OC treated group by day 14. Positive alizarin red S and von
Kossa staining was detected in the OC&BMP2 group on day 7
and the intensity of the staining increased by day 14. These results
Figure 3. Investigating the effect of increasing concentrations of inorganic phosphate on 4T1 cell mineralization. Representative
images were captured at 1006magnification and the scale bars represent 500 mm. (A) Positive alizarin red S staining for calcium (red) was observed
in the OC treated group by day 14 and on day 7 for the AA&10 mM Pi, 5 mM Pi and 10 mM Pi treated groups. (B) Positive von Kossa staining for
calcium phosphate (black/brown) was observed in the OC, AA&10 mM Pi, 5 mM Pi and 10 mM Pi on day 28. (C) The calcium content of 4T1 cells as
determined by the o-cresolphthalein calcium assay normalized to protein. Increases in calcium were observed in the OC, AA&10 mM Pi, 5 mM Pi and
10 mM Pi groups over time, with the greatest increase detected in the 10 mM Pi group. Each point represents the mean amount of calcium
measured in ppm normalized to protein measured in mg, +/2 SEM, n = 3, two-way ANOVA. *P,0.05, **P,0.01, ***P,0.001 vs. control at each time
point. OC (osteogenic cocktail) = 50 mg/ml ascorbic acid and 10 mM b-glycerophosphate. AA= 50 mg/ml ascorbic acid. Pi = inorganic phosphate.
doi:10.1371/journal.pone.0041679.g003
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Figure 4. The effect of exogenous BMP2 on 4T1 cell mineralization. Representative images were captured at 1006magnification and the
scale bars represent 500 mm. Positive staining for calcium (red) and calcium phosphate (black/brown) were observed in the OC&BMP2 group by day 7
and increased in intensity by day 14, as shown by alizarin red S (A) and von Kossa (B) staining. Positive staining was detected in the OC group by day
14 using both alizarin red S and von Kossa stains. (C) The calcium content of 4T1 cells as determined by the o-cresolphthalein calcium assay
normalized to protein. By day 14 the calcium levels of the OC&BMP2 group are 30-fold greater than the OC group. Each point represents the mean
amount of calcium measured in ppm normalized to protein measured in mg, +/2 SEM, n = 3, two-way ANOVA. **P,0.01 OC vs. control on day 14.
***P,0.001 OC&BMP2 vs. all other groups on days 7 and 14. OC (osteogenic cocktail) = 50 mg/ml ascorbic acid and 10 mM b-glycerophosphate.
BMP2= 100 ng/ml human recombinant bone morphogenetic protein 2.
doi:10.1371/journal.pone.0041679.g004
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were confirmed by a quantitative calcium assay (Figure 4C). An
increase in calcium levels were detected in the OC group on day
14 compared to the control group (P,0.01), however these
changes are overshadowed by the OC&BMP2 group at this time
point, which is ,30-fold greater than the OC group (P,0.001).
Expression of Bone Matrix Proteins during 4T1 Mammary
Cell Mineralization
4T1 cells were grown in culture plates and treated with regular
growth media (control), the osteogenic cocktail (OC) or the
osteogenic cocktail including 100 nM dexamethasone (OC&dex).
Cell monolayers were stained on day 28 with alizarin red S and
von Kossa to confirm calcium deposition. When 4T1 cells were
grown in the OC for up to 28 days, a strong positive stain for
calcium (red) and calcium phosphate (black/brown) was observed
using alizarin red S and von Kossa staining respectively
(Figure 5A). Positive staining for both alizarin red S and von
Kossa was also detected in the OC&dex group, however this was
to a much lesser extent than that observed for the OC group.
Using this established model of mammary mineralization, the
expression of several bone markers were investigated using real-
time RT-PCR from days 0–28. The 4T1 cells were found to
express col1a1 (collagen type 1, alpha 1) mRNA and there was
a general trend for upregulation of this bone marker in the OC
group compared to the control group, which was statistically
significant on days 11 (Figure 5B; P,0.05), 21 (P,0.001) and 28
(P,0.001). In contrast, there is a general trend for decreased
expression of col1a1 in the OC&dex group compared to the
control group, which was statistically significant at all time points
from days 4–28 (P,0.01 on days 11, 21 and 28; P,0.001 on days
4, 7 and 14). The 4T1 cells were also found to express bone
sialoprotein (BSP) mRNA. In the OC group, there is a statistically
significant increase in BSP expression compared to the control
group on day 21 (P,0.001; Figure 5C). There was also a 4.6-fold
decreased in BSP mRNA expression in the OC&dex group on day
11 compared to the control group. While the 4T1 cells were also
found to express Runx2 mRNA, the expression did not change
over time between the different treatment groups (Figure 5D).
Mineralization of 4T1 Cells in 3D Collagen Scaffolds
To investigate tumor cell growth and osteomimicry at the bone
metastatic site, the mineralization of the mouse mammary
adenocarcinoma 4T1 cells were grown on collagen-glycosamino-
glycan (GAG) scaffolds as the 3D structure more accurately
represents the tumor-bone microenvironment. These highly
porous scaffolds been engineered specifically for use in bone
repair and possess an optimised pore structure and composition to
facilitate adhesion and proliferation of osteoblasts [14,15]. 4T1
cells were seeded into circular dehydrothermal-crosslinked colla-
gen-GAG scaffolds and grown in the presence of the OC for up to
28 days. Positive H&E staining of 4T1 cells was observed in the
center of the scaffolds by day 14 at 4006magnification (Figure 6A)
confirming cell infiltration of the scaffold. At this time point,
partial positive staining for calcium (red) and calcium phosphate
(black/brown, counterstained with toluidine blue) were also
detected using alizarin red S and von Kossa staining respectively
(Figure 6A). By day 28, complete positive staining was observed for
both alizarin red S and von Kossa staining. This pattern of
staining is also observed at 406magnification (Figure 6B) and in
addition this magnification allows the effect of mineralization on
the scaffold structure to be observed. Minor contraction of the
scaffold appeared to take place over time from day 14 to day 28
and the collagen scaffolds appear to have disintegrated over time.
Cell viability was also monitored using an alamar blue metabolic
assay (Figure 6C) and was found to significantly increase from day
14 (22.2% reduced alamar blue) to day 28 (29.5% reduced alamar
blue; P= 0.0284).
Discussion
Mammographic microcalcifications are used for the early
detection of breast cancer in its nonpalpable form. Several studies
have shown that microcalcifications may also represent an
important diagnostic indicator. In particular, mammary micro-
calcifications composed of hydroxyapatite are associated with both
benign and malignant breast tumors, whereas calcium oxalate
tends to be associated with benign lesions of the breast [5,6,7].
However, despite the diagnostic and potential prognostic value of
microcalcifications, the mechanisms underlying their formation
and their functional role in breast cancer progression remain
unclear. In order to study this process, we have previously
established an in vitro model of mammary cell mineralization using
the metastatic 4T1 adenocarcinoma mammary cell line. These
cells are capable of depositing hydroxyapatite after treatment with
an osteogenic cocktail (OC) containing ascorbic acid and b-
glycerophosphate with or without dexamethasone [11]. We
hypothesised that under certain conditions mammary cells possess
osteomimetic capabilities that may allow them to adapt to, and
flourish within, the bone microenvironment.
In the current study, the role of the individual components of
the OC were systematically investigated. It was found that ascorbic
acid alone and dexamethasone alone do not result in 4T1 cell
mineralization. Although dexamethasone is a common addition to
osteogenic cocktails in osteogenic studies, the negative results of
the dexamethasone treatment were not surprising, as dexameth-
asone has been shown to suppress mineralization of mouse
osteoblast cells [16]. Treatment with 10 mM b-glycerophosphate
alone was sufficient to induce mineralization after 14 days. The
effect of b-glycerophosphate was found to be dose dependent as
mineralization of the 4T1 cell line was enhanced with increasing
concentrations of b-glycerophosphate using 2 mM, 5 mM and
10 mM. In addition, by day 28 it was clear that while 10 mM b-
glycerophosphate alone was sufficient to induce mineralization,
mineralization took place to a greater extent when ascorbic acid
was also included. Therefore while ascorbic acid alone does not
induce mineralization, its addition to the OC enhances the
process. Ascorbic acid is known to upregulate the production of
alkaline phosphatase [17,18], which is a well documented
enhancer of physiological mineralization [8].
In addition to using organic phosphate to induce mineralization
of the mammary cells, the effect of inorganic phosphate, an
essential and abundant physiological form of phosphate, was also
investigated. Substituting the 10 mM organic b-glycerophosphate
in the OC with 10 mM inorganic phosphate also resulted in 4T1
cell mineralization. The effect of inorganic phosphate was dose
dependent, as mineralization was enhanced with increasing
concentrations. In addition, mineralization was observed at earlier
time points when using inorganic phosphate compared to organic
phosphate. The comparative delay is likely due to hydrolysis of b-
glycerophosphate to inorganic phosphate, which is time dependent
[19]. In contrast, adding inorganic phosphate allows phosphate
ions to be immediately available for use by the cells for mineral
formation following initial treatment.
Bone morphogenetic protein 2 (BMP2) is another reagent
commonly used to enhance osteoblast mineralization in vitro
[20,21,22,23,24]. BMP2 is also known to be expressed in human
breast cancers [25,26] and injection of recombinant BMP2 into
growing rodent mammary tumors results in mammary micro-
Osteomimicry of Mammary Adenocarcinoma Cells
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Figure 5. Investigating the expression of several bone markers in mineralizing 4T1 cells using real-time RT-PCR. (A) Alizarin red S and
von Kossa staining of 4T1 cells after 28 days as viewed under a light microscope at 1006magnification (n = 3). The scale bar represents 500 mm.
Positive staining was observed for calcium (red) and calcium phosphate (black/brown) using alizarin red S and von Kossa staining respectively, in the
OC group and to a lesser extent in the OC&dex group. (B) There is a decrease in col1a1 (collagen type 1, alpha 1) mRNA expression in the OC&dex
Osteomimicry of Mammary Adenocarcinoma Cells
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calcifications [27]. Therefore, the hypothesis that BMP2 may
enhance 4T1 cell mineralization was investigated. It was found
that 100 ng/ml BMP2 alone did not enhance 4T1 mineralization
in vitro. However, when 100 ng/ml BMP2 was used in combina-
tion with the OC, mineralization was 30-fold greater compared to
the OC alone. It is likely that within the tumor microenvironment,
mammary cells that express BMP2 could use any available source
of phosphate to produce mammary microcalcifications. While the
source of phosphate used to produce microcalcifications in vivo
remains unexplored, phosphate is abundant in the human body. It
is feasible that within the tumor microenvironment, highly
group compared to the control group from days 4–28. In contrast, there is increased expression of col1a1 in the OC group on days 11, 21 and 28.
*P,0.05 OC vs. control on day 11. **P,0.01 OC&dex vs. control on days 11, 21 and 28. ***P,0.001 OC vs. control on days 21 and 28, also OC&dex vs.
control on days 4, 7 and 14. (C) On day 21 there is an increase in the expression of bone sialoprotein (BSP) mRNA in the OC group compared to the
control and OC&dex groups. ***P,0.001 OC vs. control and OC&dex groups on day 21. (D) No changes in the expression of Runx2 mRNA were
detected between the different treatment groups over time. All real-time RT-PCR results are expressed in arbitrary units and normalized to the control
samples at each time point. Each point represents the mean +/2 SEM, n = 3, two-way ANOVA. OC (osteogenic cocktail) = 50 mg/ml ascorbic acid and
10 mM b-glycerophosphate. Dex = 100 nM dexamethasone.
doi:10.1371/journal.pone.0041679.g005
Figure 6. Assessingmineralization of 4T1 cells grown in an osteogenic cocktail within 3D collagen scaffolds. Representative images are
shown at 4006 and 406magnifications and the scale bars represent 200 mm and 2000 mm respectively. (A) Positive hematoxylin and eosin (H&E)
staining was observed at 4006magnification by day 14 and the intensity of the hematoxylin stain increased by day 28. Some positive alizarin red S
staining for calcium (red) was detected by day 14. Complete positive staining with alizarin red S and von Kossa (including toluidine blue counterstain)
was observed by day 28. (B) At 406 magnification the previously described patterns of staining are confirmed and minor contraction and
disintegration of the scaffolds are observed over time. (C) Assessing cell viability of 4T1 cells grown within the 3D scaffolds using an alamar blue
metabolic assay. An increase in cell viability was detected between day 14 and day 28. Each time point represent the mean % reduction in alamar
blue +/2 SEM, n= 3, students t-test. *P = 0.0284 day 28 vs. day 14. OC (osteogenic cocktail) =with 50 mg/ml ascorbic acid and 10 mM b-
glycerophosphate.
doi:10.1371/journal.pone.0041679.g006
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proliferative cancer cells may produce a localized increase in
phosphate, which could lead to mineral deposition.
In order to elucidate the molecular mechanism involved in
mammary mineralization, an area that remains largely unin-
vestigated, the expression of several bone markers were charac-
terized using real-time RT-PCR. It was found that collagen type 1
alpha 1 (col1a1) and bone sialoprotein (BSP) mRNA were
upregulated on day 21 in the mineralizing OC treated 4T1 cells.
Both col1a1 and BSP are well documented enhancers of
physiological mineralization and increased expression has been
reported in the literature during this process [8,28]. BSP is thought
to act by nucleating hydroxyapatite [29]. Therefore BSP may play
a similar role during mammary mineralization, especially as
elevated BSP has been documented in human breast cancers
[30,31,32], particularly in tumors containing microcalcifications
[12]. The role of collagen type 1 during bone formation is to form
a network of fibres, which support the growth of hydroxyapatite
crystals [33,34,35]. Collagen is also a major component of the
extracellular matrix of breast tissue and therefore may play
a similar role as a natural scaffolding to support crystal growth.
Dysregulation of collagen has been documented for breast cancer,
as malignant breast tumors have increased collagen type 1 mRNA
expression compared to benign breast tissue [36]. However, this is
the first evidence to suggest that collagen may be associated with
mammary microcalcifications.
The pattern of bone marker expression reported here adds
weight to our hypothesis that the 4T1 cells mineralize in an active,
regulated manner using a mechanism similar to osteoblasts.
However, no changes in the expression of Runx2 mRNA were
detected in the mineralizing 4T1 cells. Runx2 is widely considered
to be involved in physiological mineralization by upregulating the
expression of several bone matrix proteins including col1a1 and
OPN [37,38]. While Runx2 is the most well documented
transcription factor associated with physiological mineralization,
many others have been reported including osterix, Runx3 and
calcineurin [39,40,41]. Therefore future studies will focus on their
expression and potential involvement in mammary mineralization.
Having established and characterized the in vitro model of 4T1
cell mineralization in monolayer, next we focused on further
developing this model in order to study bone metastasis. This was
achieved using 3D collagen scaffolds, which are highly porous
engineered biomaterials that have been well documented as
supporting the growth and mineralization of osteoblasts
[15,42,43]. While engineered biomaterials were originally de-
veloped for direct clinical applications, this technology has become
a powerful tool in other biomedical research areas, including
cancer research [44]. Cell growth in 3D is more reminiscent of
physiological growth, compared to cells grown in monolayer [44].
3D models may help bridge the gap between traditional 2D
monolayer cell culture methods and animal models [44]. The
scaffolds used in this study provide a 3D array of collagen fibres
that support hydroxyapatite crystal growth in a manner that
mimics the bone microenvironment. It was shown here for the first
time that the scaffolds are capable of supporting the growth of
adenocarcinoma mammary cells, as the 4T1 cells were seen to
fully infiltrate the scaffolds by day 14 as shown by H&E staining of
OC treated samples. It was also found that the mammary 4T1
cells are capable of mineralizing within this 3D environment in
a similar manner to that previously reported for the 4T1 cells
grown in monolayer. Mineralization of the 4T1 cells began on day
14 in the 3D scaffolds and extensive mineralization was observed
by day 28. It was also shown that cell viability was not
compromised for up to 28 days and while minor contraction
and disintegration of the scaffolds took place, this did not affect the
process of mineralization. These bioengineered scaffolds represent
a novel system for the study of mammary mineralization within
the tumor-bone microenvironment.
In summary we have shown that mammary adenocarcinoma
4T1 cells are capable of osteomimicry. Exogenous sources of
phosphate and BMP2 were found to enhance mineralization of the
4T1 cell line, which has been well documented in osteoblast
cultures. In addition, we have shown that the bone matrix proteins
col1a1 and BSP are differentially expressed during the process of
mammary mineralization in vitro. Also for the first time, it was
shown that mammary cells are capable of mineralizing within a 3D
collagen scaffold. Through expression of bone marker proteins and
their capacity for growth and infiltration within a highly collag-
enous setting, adenocarcinoma cells demonstrate their innate
ability to adapt to the hydroxyapatite rich microenvironment of
bone. We suggest that mammary mineralization is not simply
a process of cellular degeneration as has previously been suggested,
but an actively regulated osteomimetic process that may have
functional consequences contributing to breast cancer metastasis
to bone.
Materials and Methods
Cell Lines and Media
The murine mammary adenocarcinoma 4T1 cell line is
available from ATCC [45]. This cell line was maintained in
a regular growth media consisting of low glucose DMEM, 10%
FBS and 1% penicillin/streptomycin. All cell culture reagents
were purchased from Sigma-Aldrich (Ireland and Biosera, UK).
Induction of Mineralization
4T1 cells were seeded into 6-well culture plates (day 21) at
a density of 1.56105 cells/well and the following day (day 0) the
cells were treated with regular growth media with/without the
following: an osteogenic cocktail (50 mg/ml ascorbic acid, 10 mM
b-glycerophosphate with or without 100 nM dexamethasone),
50 mg/ml ascorbic acid, 100 nM dexamethasone, or increasing
concentrations of b-glycerophosphate or inorganic phosphate
(2 mM, 5 mM and 10 mM). In addition, the effect of recombinant
human bone morphogenetic protein 2 (BMP2; ebiosciences,
Hatfield, UK) on 4T1 cell mineralization was also investigated
by adding 100 ng/ml to regular growth media or media contain-
ing the osteogenic cocktail. Cells were maintained in an
atmosphere of 37uC and 5% CO2 and half of the media was
replenished every three days for up to 28 days.
For 3D studies, in-house engineered circular collagen-glycos-
aminoglycan (GAG) scaffolds with a diameter of 12.5 mm were
seeded with 26106 4T1 cells. These scaffolds are fabricated using
a lyophilisation technique [46,47] which results in a highly porous
(.99%) structure. Following lyophilisation, the scaffolds were
crosslinked using a dehydrothermal process [14] in a vacuum oven
at a temperature of 105uC. This process improves the mechanical
properties of the scaffolds and also sterilises them for cell culture.
Scaffolds were maintained in regular growth media for 2 days and
were then treated with media containing the osteogenic cocktail
(50 mg/ml ascorbic acid and 10 mM b-glycerophosphate). Cells
were maintained at 37uC and 5% CO2 and samples were taken for
analysis at 14 and 28 days. The scaffolds were fixed in formalin
(10%) for 30 min at room temperature and placed in a Leica ASP
300 tissue processor overnight. The scaffolds were then cut in half
and embedded in wax either horizontally or vertically. Samples
were sectioned (10 mm) using the Leica RM2255 microtome
(Nussloch, Germany). The sections were mounted onto polysine
coated slides (Fisher Scientific, Loughborough, UK) and kept at
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room temperature until histological staining was carried out as
described below.
Histological Staining
4T1 cell monolayers were fixed with 10% formalin for 30 min
followed by staining with alizarin red S (2%, pH 4.4, 4 min). For
von Kossa staining, fixed cells were incubated with silver nitrate
(5%) for 1 hour under an electric lamp, which was followed by
sodium thiosulphate (5%) treatment for 2 min. For paraffin
embedded scaffolds, serial sections (10 mm) were deparaffinised
using xylene and rehydrated through a series of ethanol washes
prior to staining with alizarin red S, von Kossa (using toluidine
blue counterstain) or hematoxylin and eosin (H&E). Samples were
dehydrated, incubated with xylene (30 min) and mounted with
DPX. Images were captured using the Nikon Eclipse TS100
inverted microscope and Nikon Digital Sight DS-L1 camera
system (Amstelveen, The Netherlands).
Alamar Blue
Cell viability was monitored for cells grown in 3D collagen
scaffolds using an alamar blueH metabolic assay according to the
manufacturer’s instructions (Invitrogen, California, USA). Briefly,
cell cultures were incubated with Alamar blueH (10% in regular
growth media) at 37uC for 2 hours. The absorbance of the media
from each well was measured in triplicate at 540 nm and 620 nm
in a spectrophotometer and analysis was carried out according to
the manufacturer’s instructions.
Quantitative Calcium Assay
Calcium was extracted by incubating 4T1 cell monolayers with
nitric acid (1 M; 1 hr). The absorbance of the samples when
reacted with o-cresolphthalein (0.1 mg/ml) and 2-amino-2-meth-
yl-1-propanol (90 mg/ml) was read at 572 nm [48]. A BCA
protein assay (Novagen, Darmstadt, Germany) was performed on
duplicate samples. The cells were suspended in RIPA lysis buffer
(16 PBS; 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS)
containing 1% protease inhibitor cocktail (Sigma Aldrich, Arklow,
Ireland), stored on ice for 1 hr with occasional vortexing and
centrifuged at 12000 rpm for 20 min. The BCA protein assay was
carried out on the supernatant according to the manufacturer’s
instructions.
Real-time RT-PCR
Total RNA was extracted from 4T1 cells using trizolH
(Invitrogen, California, USA) and was reverse transcribed using
a high-capacity cDNA reverse transcription kit (Applied Biosys-
tems, California, USA). Real-time RT-PCR was carried out using
the real-time PCR thermocycler (Applied Biosystems 7500) for
col1a1 (QT00162204, Qiagen, Hilden, Germany), bone sialopro-
tein (QT00115304, Qiagen) and Runx2 (QT00102193, Qiagen),
using 18 s (QT01036875, Qiagen) as an endogenous control.
Samples were heated at 95uC for 15 min. This was followed by
a second stage of 15 sec at 94uC, 30 sec at 55uC, and 45 sec at
72uC, which was repeated 40 times.
Statistical Analysis
All statistical analysis was carried out using GraphPad Prism 5
software (La Jolla, CA, USA). When comparing two groups,
students t-tests were used. When analyzing multiple treatments
over multiple time points, a two-way ANOVA was used. Post-hoc
analysis was carried out when a significant p value of less than 0.05
was detected.
Supporting Information
Figure S1 Visualisation of nodule formation with alizarin red S
staining of 4T1 cells (positive for calcium (red)) treated with the
OC on day 11. Representative image was taken at 1006
magnification (n = 3). OC (osteogenic cocktail) = 50 mg/ml ascor-
bic acid and 10 mM b-glycerophosphate.
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